Summary P-glycoprotein gene (mdrl) amplification and expression were examined in murine leukaemia P388/DX and melanoma B16VDXR cell lines, which exhibit a high level of resistance to a selecting agent, doxorubicin, and express a multidrug-resistant phenotype because they are cross-resistant to multiple cytotoxic drugs. The multidrug-resistant phenotype was obtained in different conditions of selection (in vivo and in vitro for P388/DX and B16VDXR, respectively). In both multidrug-resistant cell lines, an increased expression of P-glycoprotein gene (5 kb transcript detected in Northern blots) was observed and the level of Pglycoprotein mRNA correlated with the degree of resistance. In addition, high molecular weight mRNAs homologous to mdrl gene sequence were consistently detected only in P388/DX cells. Overexpression was associated with a high level of gene amplification only in resistant melanoma cells, whereas it occurred in P388/DX cells with a marginal increase in gene copy number. These results, suggesting that different genetic mechanisms could be responsible for P-glycoprotein overexpression, emphasise the complexity of genetic regulation that may affect tumour cell sensitivity to cytotoxic agents.
Several lines of evidence have indicated that increased expression of a high molecular weight membrane glycoprotein (P-glycoprotein) is responsible for multidrug-resistant phenotypes (Riordan et al., 1985; Scotto et al., 1986) . Using cDNA clones encoding for P-glycoprotein, isolated from a number of mammalian cells, it has been demonstrated that P-glycoprotein genes (also termed mdrl genes) are amplified and overexpressed in multidrug-resistant cell lines (Gros et al., 1986a; Roninson et al., 1986) . Nevertheless, multidrug resistance in mammalian tumour cells is probably due to multiple molecular mechanisms (Beck et al., 1987; Mirski et al., 1987; Capranico et al., 1987) .
Although gene amplification is reported to be the most frequent mechanism of drug resistance (Schmike, 1984) , the genomic organisation and control of gene(s) involved in the phenomenon of multidrug resistance has not been clearly defined. In an attempt to throw light on the genetic basis of multidrug resistance, we analysed mdrl gene amplification and expression in murine doxorubicin-resistant melanoma B16VDXR and leukaemia P388/DX cells. These cell lines were selected since they exhibit a high level of resistance and express a typical multidrug-resistant phenotype. Resistant P388/DX and B16VDXR cell lines were developed independently under different conditions of selection with in vivo and in vitro doxorubicin treatments, respectively. P388/ DX, a well established cell line, showed an overall higher degree of resistance than the B16VDXR cell line developed more recently in vitro. of mouse mdrl gene, was kindly provided by Dr P. Gros (Gros et al., 1986b) . After digestion of plasmid DNA with restriction enzymes EcoRI and Sall, the 1.3kb fragment was isolated by agarose gel and then used as a probe for Northern and Southern blot hybridisations. A mouse f3-actin probe was derived from plasmid pAL41 (Alonso et al., 1986) .
Materials and methods

Materials
Murine tumour lines Sensitive and resistant P388 cell lines were maintained in mice by weekly i.p. transplantation, as already described (Capranico et al., 1986) . Melanoma B16VDXR cell line was selected in vitro from cultured sensitive B16 cell line with doxorubicin by stepwise increases in drug concentration Formelli et al., 1986) . For Cathala et al. (1983) . The poly(A)+ RNA fraction was separated on an oligo(dT)-cellulose column (Pharmacia, Uppsala, Sweden). Northern gel electrophoresis and blot hybridisation were performed essentially according to reported procedures (Maniatis et al., 1982) . Briefly, total or poly(A)+ RNAs were size fractionated on denaturing 1% agarose gels; then gels were equilibrated in 20xSSC before overnight blotting to nitrocellulose (BioRad, Milan, Italy). The filters were baked at 80°C and then prehybridised for at least 4 h at 42°C in 50% formamid, 5 x SSC, 0.2% SDS, 5 x Denhardt solution, 50 mM sodium phosphate, pH 7.0, 250 ig ml-1 of salmon sperm DNA. The mouse mdrl DNA sequence used in this study is derived from plasmid pcDR 1.3, which contains a 1.3 kb fragment of a full length mdr cDNA capable of conferring a multidrugresistant phenotype (Gros et al., 1986b) . Our findings show that mdrl gene is overexpressed in P388/DX and B16VDXR cells, strongly suggesting that P-glycoprotein may contribute to the high degree of resistance of these two resistant cell lines (Table I) (Bradley et al., 1988) . This is not the case of P388/DX, characterised by a high degree of resistance. In contrast, the high level of gene amplification found in B 1 6VDXR reflects a more commonly described phenomenon, although this line has been recently developed. These observations favour the hypothesis that alterations at transcription level are a critical step in the development of multidrug resistance.
Relevant to this point is the observation that a revertant cell line of a multidrug-resistant human leukaemia has shown greatly decreased P-glycoprotein mRNA levels, without a corresponding loss of amplified DNA (Sugimoto et al., 1987) . Altogether, these findings indicate that mdrl gene can be activated or inactivated at the level of transcription, regardless of gene copy number in the cellular genome, thus emphasising the complexity of genetic regulation that may affect cell sensitivity to cytotoxins. In general, the study of multidrug resistance in P388/DX cells has revealed that complex biochemical and genetic mechanisms are involved in cell protection against cytotoxins. In particular, molecular alterations at a nuclear level are, at least in part, responsible for the high degree of drug resistance of these cells (Capranico et al., 1986 .
Taken together with previous observations, these results further support the idea that multidrug-resistant phenotypes may arise from multiple molecular and genetic alterations in mammalian cancer cells Beck et al., 1987) . The relative role of these molecular modifications might differ markedly among different tumour cell lines depending on several factors including the origin of the multidrug-resistant tumour line (Hill & Bellamy, 1984) . It still remains to be determined if the manner in which resistant cells are obtained (i.e. in vivo or in vitro selection with doxorubicin) can influence the genetic mechanism of antitumour drug resistance.
